Ablynx drug fails in mid-stage lupus trial
After losing out to Sanofi in its pursuit of Belgian biotech Ablynx earlier this week, Novo Nordisk has put a brave face on the disappointment.
New trial data will be included in US and EU filings
European regulators are already reviewing caplacizumab
Collaboration will develop drugs for inflammatory diseases